Clinical characteristics of Covid-19 patients with re-positive test

results: an observational study

Ying Su^{1,*}, Ling-Shuang Zhu^{2,3,*}, Yong Gao⁴, Yuncheng Li⁵, Zhanlu Xiong⁶, Bo Hu¹, Jiao Yuan⁷, Zhao Zhang⁸, Xiaoxiong Wu⁹, Chunchen Feng¹, Fanjun Cheng¹⁰, Yang Jin¹¹, Yu Zhang¹², Youming Lu¹³, Hongbo Wang^{14,#}, Ling-Qiang Zhu^{2,3,#}

¹Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

²Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China

³Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

⁴Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁵Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁶General office, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁷Biobank, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁸Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

⁹Department of Emergency, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

¹⁰Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

¹¹Key Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

¹²Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

¹³Department of Physiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

¹⁴Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

* These authors contributed equally to this article.

Corresponding authors

Ling-Qiang Zhu, zhulq@mail.hust.edu.cn

Hongbo Wang, hb_wang1969@sina.com

Abstract

Background: With coronavirus disease 2019 (Covid-19) ravaging the global, concern has been aroused whether discharged Covid-19 patients with reappeared positive nucleic acid test results are infected again.

Objective: To analyze the clinical characteristics of discharged Covid-19 patients with reappeared positive nucleic acid test results and to track clinical outcomes of them.

Methods: We extracted clinical data on 938 Covid-19 patients from Wuhan Union Hospital (West Branch), and we obtained information about residual symptoms and nucleic acid tests after discharge through follow-up study. We evaluated the relationship of clinical characteristics and reappeared positive results. Each patient had at least 44 days of follow-up.

Results: Of 938 discharged patients, a total of 58 (6.2%) had reappeared positive nucleic acid test results and 880 remain negative. Among patients over the age of 50, the factors we found to be associated with re-positive results were coronary artery disease (14.1%, vs. 5.5% among those without coronary artery disease; odds ratio, 2.81; 95% confidence interval [CI], 1.28 to 6.15), and hypertension (9.5%, vs. 4.9% among those without hypertension; odds ratio, 2.05; 95% CI, 1.10 to 3.82). As of May 11, 2020, 54 (93.1%) re-positive patients turned negative again while two patients remained positive, and two patients was lost to the second follow-up.

Conclusion: Coexisting diseases including coronary artery disease and hypertension were substantial risk factors for re-positive outcomes among patients over 50. And most re-positive patients tended to return negative eventually.

Introduction

Covid-19 pandemic continues to ravage the global, with 8974795 confirmed cases and 469159 documented deaths as of June 23, 2020 (1). Real-time reverse transcription polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely carried out as a diagnostic and discharge criterion (2). However, recent reports regarding positive SARS-CoV-2 test results in some recovered cases after discharged home were published (3-6). Concern has been aroused that these recovered patients with a reappeared positive test might be infected and contagious again, given that no evidence suggests people with Covid-19 antibodies protected from second infection (7).

Among the main possibilities on the re-detectable positive results are second infection, relapse, or RNA fragment detection. Second infection would be the worst-case scenario due to the impediment to vaccine development and herd

immunity (8, 9). It has been suggested that patients tested positive again were unlikely to relapse, because no live virus was isolated in them and positive tests may result from inactive virus fragment. But a recent report suggests that patients may still carry SARS-CoV-2 deep in the lungs after recovery and discharge, and the presence of virus cannot be detected by conventional nucleic acid test from nasopharyngeal swabs (10).

It is crucial to figure out susceptibility of convalescent patients to the re-positive experience as well as clinical outcomes of it. Therefore, we undertook a research to study the relationship between reappeared positive test results and clinical features.

Methods

Study oversight

The study was approved by the institutional review board of Wuhan Union Hospital and designed by the authors. Data were analyzed and interpreted by the authors. All the authors had full access to the data and vouch for the accuracy and completeness of the data. All the author claimed responsible for the decision to submit the manuscript for publication.

Study population and data collection

We collected the medical records and compiled data of 1208 hospitalized patients with laboratory-confirmed Covid-19 in Wuhan Union Hospital (West Branch), who were discharged between January 18, 2020 and March 26, 2020. A positive Covid-19 case was defined as a positive result on high-throughput sequencing or RT-PCR assay of nasal and pharyngeal swab specimens. As of April 24, 2020, we carried out the first telephone follow-up survey on these 1208 discharged patients, 938 cases of which finished follow-up study. 270 cases were lost mainly due to wrong phone numbers, unanswered calls, and incoordinate patients. A second follow-up was targeted on 58 re-positive patients as of May 11, 2020, and 56 patients finished it.

We extracted patients' demographic and clinical characteristics from electronic medical records, including age, sex, length of hospital stays, severity on admission, and coexisting diseases. Coexisting diseases included cardiovascular disease (including cardiac dysfunction, coronary artery disease, and hypertension), respiratory disease (asthma and chronic bronchitis), autoimmune disease, cancer, diabetes mellitus, hepatic dysfunction, and renal dysfunction. We obtained clinical information after discharge through follow-up survey, including residual symptoms and laboratory re-examinations results on SARS-COV-2 nucleic acid, chest imaging, and serum antibody. Residual symptoms included chest congestion, palpitation, expectoration, cough, fatigue, dry eyes, myalgia, sore throat, headache, diarrhea, and fever.

Study definitions

Fever was defined as an axillary temperature of 37.3°C or higher.

Mild and moderate Covid-19 patients were defined as patients who had mild clinical symptoms with or without pneumonia on chest imaging. Severe and critically

ill patients were patients meeting up to any of the following standards: respiratory rate (RR) ≥ 30 times/minute; finger oxygen saturation $\leq 93\%$ at rest; the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen [Pao₂:Fio₂], ≤ 300 mmHg (1 mmHg = 0.133 kPa).

Discharge criterion was defined as follows: Temperature returned back to normal for over three days with respiratory symptoms significantly improved; chest imaging showed inflammation absorption; and two consecutive nucleic acid tests for SARS-COV-2, sampling interval of which exceeded 24 hours, were negative.

Statistical analysis

Continuous variables were reported as means and standard deviations. Categorical variables were summarized as counts and percentages.

Independent-sample T test or T' test was completed to assess the differences between male and female groups. Mann-Whitney U test, χ^2 test, or Fisher's exact test were used to compare differences between re-positive and negative groups where appropriate. The category of analyzed diseases and symptoms was decided according to re-positive patients. If the patient's electronic medical record and follow-up record did not include information on a clinical characteristic, such as hypertension or cough after discharge, that characteristic was assumed not present.

Age- and sex- adjusted linear regression analyses were performed to confirm the relationship between re-positive test results and symptoms after discharge (chest congestion, palpitation, expectoration, cough, fatigue, dry eyes, myalgia, sore throat, headache, diarrhea, and fever). Age- and sex- adjusted linear regression analyses were performed to confirm the relationship between coexisting diseases (diabetes mellitus, coronary artery disease, hypertension, and coexisting conditions) and re-positive tests, with odds ratios and 95% confidence intervals calculated. The 95% confidence intervals have not been adjusted for multiple testing and should not be used to infer definitive effects.

All statistical analyses were performed with SPSS Statistics software, version 26 (IBM).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

1. Demographic and Clinical Characteristics

As of April 24, 2020, our first follow-up study population included 938 patients

(510 female cases) hospitalized for Covid-19 in Wuhan Union Hospital (West Branch) who were discharged between January 18, 2020 and March 26, 2020 (Figure 1). Among them, 14.9% were mild and moderate patients, 85.1% were severe and critically ill (Table 1). The mean ($\pm$ SD) age of the patients was 57.0 ± 14.6 years (range, 16 to 94 years). A majority of the patients (72.6%) were above 50 years. Severe and critically ill patients were older than mild and moderate patients by 5.3 years. And the mean ($\pm$ SD) length of hospital stay was 21.3 ± 11.5 days (range, 1 to 59 days) (Table S1-2).

462 (49.3%) patients had residual symptoms after discharge. The most common symptoms were chest congestion and palpitation, which respectively occurred in 192 (20.5%) and 154 (16.4%) patients. 128 (13.6%) had expectoration, 124 (13.2%) patients had cough, 111 (11.8%) patients had fatigue, and 109 (11.6%) had dry eyes. Other symptoms included myalgia (7.7%), sore throat (6.5%), headache (5.7%), diarrhea (3.6%), and fever (1.7%) (Table 1). Women had a great prevalence of chest congestion, palpitation, cough, fatigue, myalgia, and headache, whereas no association was found between gender and other five symptoms (Table S2).

2. Characteristics of Retested Positive (RP) Patients Compared with Retested Negative (RN) Patients

Fifty-eight (6.2%) patients were tested positive again in nucleic acid tests after discharge. The mean ($\pm$ SD) age and mean ($\pm$ SD) length of hospital stay of RP patients was respectively 57.8 ± 13.4 years (range, 19 to 79 years) and 19.2 ± 9.5 years (range, 4 to 42 days), with no difference between RP and RN group (Table S3).

Coexisting diseases were common among both RP and RN patients. Twenty-one (36.2%) RP patients had hypertension and 11 (19.0%) had diabetes mellitus. Nine (15.5%) had coronary artery disease, three (5.2%) had cardiac dysfunction, two (3.4%) had cancer, and one (1.7%) had chronic bronchitis. And no association between coexisting diseases and RP patients was found within the full sample. Residual symptoms after discharge were more common in RP patients. Twenty-three (39.7%) RP patients had chest congestion, 15 (25.9%) had cough, 13 (22.4%) had dry eyes, 13 (22.4%) had palpitation, 11 (19.0%) had fatigue, and 11 (19.0%) had expectoration. Particularly, RP patients were more likely to regain chest congestion, cough, diarrhea, dry eyes, and fever after discharge (Table S3-4).

3. Linear Regression Analysis Based on Re-Positive Patients over 50

The most common coexisting diseases among RP patients were hypertension, diabetes mellitus, and coronary artery disease. Noticeably, all of these diseases were mainly distributed in RP patients over 50 years old. And RP patients had higher prevalence than RN patients, especially coronary artery disease and hypertension (Table S5).

Age- and sex-adjusted linear regression models were used to analyze relationship between coexisting diseases and re-positive nucleic acid results. The odds ratios and coefficients were present in Table 2 and Table S6. Coronary artery disease and hypertension were associated with a higher risk of re-positive test results. For

coronary artery disease, the odds ratio was 2.81 (95% confidence interval [CI], 1.28 to 6.15) and coefficient was 0.089 (95% CI, 0.026 to 0.151). For hypertension, the odds ratio was 2.05 (95% confidence interval [CI], 1.10 to 3.82) and coefficient was 0.048 (95% CI, 0.008 to 0.088). Although no association was found in diabetes mellitus (odds ratio, 1.57; 95% CI, 0.75 to 3.29), we were surprised to find that coexisting of diabetes mellitus rose the odds ratio and coefficient of coronary artery disease to 8.46 (95% CI, 3.01 to 23.80) and 0.286 (95% CI, 0.173 to 0.398) respectively.

4. Clinical Outcomes of 58 RP Patients

Forty-one RP patients received chest CT imaging after discharge, with 37 (90.2%) cases showing improvement. And 29 patients received serum IgG and IgM tests. Twenty-two (75.9%) patients were IgG positive and IgM negative, five (17.2%) patients were both positive, while two (6.9%) patients were both negative.

Two patients were lost to the second follow-up for RP patients. Among the rest patients, 54 (93.1%) turned negative again while two patients remained positive as of May 11, 2020. The mean interval ($\pm$ SD) of turning positive after discharge was 12.2 ± 5.7 days (range, 3 to 39 days) and mean interval ($\pm$ SD) of turning negative again was 12.9 ± 13.2 days (range, 1 to 53 days). As of May 11, 2020, the percentage of RP patients with residual symptoms sharply declined from 67.0% at discharge to 16.7%. Three (5.5%) patients had fatigue, two (3.7%) had cough, two (3.7%) had chest congestion. There was only one (1.9%) patient with expectoration, one (1.9%) with throat, and one (1.9%) with palpitation.

Discussion

In this follow-up analysis that included 938 Covid-19 patients, no evidence indicated that age, sex or severity was associated with re-positive outcomes. Harmful associations were noted for coronary artery disease and hypertension among patients over 50 years old. Considering the urgency of the pandemic and the uncertainty of re-positive patients, we chose to report our findings before collecting a larger sample to provide clinical advice to focus on patients with coronary heart disease and hypertension over the age of 50.

Comorbidities such as coronary heart diseases, hypertension and diabetes predisposed to detrimental clinical outcomes in Covid-19 patients (11-13). Evidence was found that patients may still carry SARS-CoV-2 deep in the lungs after recovery, which cannot be detected by conventional nucleic acid test for upper respiratory tract (12). Some patients may still carry a low load of SARS-Cov-2 virus at discharge, whereas impaired immunity due to comorbidities could result in a larger fluctuation in virus load and therefore a re-positive state several days later. Besides, a recent study pointed out that hypertension was a prominent risk factor preventing viral clearance in Covid-19 patients (14). SARS-Cov-2 enters cells using angiotensin-converting enzyme2 (ACE2) (15, 16), which is a widely-expressed membrane-bound aminopeptidase in heart, kidney and lung (17, 18). Treatment of ACE inhibitors or angiotensin II type-1 receptor blockers (ARBs) on patients with hypertension results

in a substantially increased expression of ACE2 (19, 20), which increases risk of virus invasion and difficulty of clearance.

Despite that mechanisms underlying re-positive outcome remain unclear, the possibility of secondary infection is small because these RP patients caused no infection after discharge and most of them returned negative again with an alleviation in symptoms. As of May 11, 2020, the percentage of RP patients with residual symptoms sharply declined, and 93.1% RP patients turned negative again.

Our study has several limitations. First, the short duration of follow-up makes it hard to determine clinical ends of RP patients. It is uncertain whether they will remain negative or turn positive again. Long-term follow-up are needed to evaluate the possible risk of re-positive patients. Second, some patients had incomplete medical documentation. The anamnesis was considered inexistent if not documented. Third, because Wuhan Union Hospital (West Branch) mainly treats severe and critically ill patients, only 140 mild and moderate patients were included in the follow-up study. It is uncertain whether the conclusions can be generalized to mild and moderate patients. Finally, due to our focus on characteristics of re-positive patients, more attention was paid to harmful factors and some protective factors may be missed.

In summary, we demonstrated coronary artery disease and hypertension were associated with an increased risk of re-positive test results for patients over 50. However, re-positive patients tended to turn negative eventually. Our findings also highlight the importance of following up discharged patients because two consecutive negative nucleic acid tests at discharge were not necessarily the endpoints.

References

1. World Health Organization. Coronavirus disease (COVID-19) outbreak. <http://www.who.int/emergencies/diseases/novel-coronavirus-2019/> (accessed June 23, 2020).
2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020; **25**(3): 2000045.
3. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)* 2020; **133**(9): 1039–43.
4. Zhang B, Liu S, Dong Y, et al. Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19). *J Infect* 2020; published online Apr 23. DOI: 10.1016/j.jinf.2020.04.023.
5. Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. *JAMA* 2020; **323**(15): 1502–3.
6. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. *J Med Virol* 2020; published online Apr 9. DOI: 10.1002/jmv.25855.
7. World Health Organization. "Immunity passports" in the context of COVID-19. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19/> (accessed May 10, 2020).
8. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. *Immunity* 2020;

52(4): 583–9.

9. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. *Nat Rev Immunol* 2012; **12**(8): 592–605.
10. Yao XH, He ZC, Li TY, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. *Cell Res* 2020; **30**(6): 541–3.
11. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020; **55**(5): 2000547.
12. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med* 2020; published online May 1. DOI: 10.1056/NEJMoa2007621.
13. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**(18): 1708–20.
14. Chen XP HW, Ling JX. Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients. *medRxiv March* 2020; published online March 24. DOI: <https://doi.org/10.1101/2020.03.22.20040774>.
15. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veasler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020; **181**(2): 281–92 e6.
16. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020; **367**(6485): 1444–8.
17. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol Rev* 2018; **98**(1): 505–53.
18. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005; **436**(7047): 112–6.
19. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. *Pharmacol Res* 2017; **125**(Pt A): 21–38.
20. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; **366**(9502): 2026–33.

Acknowledgments

This study is supported partially by the National Natural Science Foundation of China (81871108, 81829002, 81961128005, 81761138043, 31721002), Top-Notch Young Talents Program of China of 2014, and Academic Frontier Youth Team of Huazhong University of Science and Technology to Dr. Ling-Qiang Zhu.

Table 1. Demographic and Clinical Characteristics of 938 Patients

Characteristic	All Patient	Male	Female
----------------	-------------	------	--------

	(N=938)	(n=428)	(n=510)
Severity of illness, n (%)			
Mild and moderate	140 (14.9)	54 (12.6)	86 (16.9)
Severe and critically ill	798 (85.1)	374 (87.4)	424 (83.1)
Mean age (range), year	57.0±14.6 (16-94)	56.9±14.0 (16-94)	57.1±15.1 (18-94)
Mean length of hospital stay (range), day	21.3±11.5 (1-59)	21.2±11.2 (4-59)	21.3±11.7 (1-54)
Positive retests after discharge, n (%)	58 (6.2)	30 (7.0)	28 (5.5)
Residual symptoms after discharge, n (%)			
Chest congestion	192 (20.5)	68 (15.9)	124 (24.3)
Cough	124 (13.2)	43 (10.0)	81 (15.9)
Diarrhea	34 (3.6)	18 (4.2)	16 (3.1)
Dry eyes	109 (11.6)	42 (9.8)	67 (13.1)
Expectoration	128 (13.6)	50 (11.7)	78 (15.3)
Fatigue	111 (11.8)	35 (8.2)	76 (14.9)
Fever	16 (1.7)	7 (1.6)	9 (1.8)
Headache	53 (5.7)	11 (2.6)	42 (8.2)
Myalgia	72 (7.7)	21 (4.9)	51 (10.0)
Palpitation	154 (16.4)	50 (11.7)	104 (20.4)
Sore throat	61 (6.5)	24 (5.6)	37 (7.3)

Plus-minus values are means ±SD.

Table 2. Independent Predictors of Re-Positive Result from Linear Regression

Risk Factor	Risk Factor	Risk Factor	Odd Ratio (95% CI)
	Present n of RP patients/total n (%)	Absent	
Diabetes mellitus	10/113 (8.8)	33/568 (5.8)	1.57 (0.75 to 3.29)
Coronary artery disease	9/64 (14.1)	34/617 (5.5)	2.81 (1.28 to 6.15)
Hypertension	20/210 (9.5)	23/471 (4.9)	2.05 (1.10 to 3.82)
Diabetes mellitus and coronary artery disease	6/18 (33.3)	37/663 (5.6)	8.46 (3.01 to 23.80)
Coronary artery disease and hypertension	7/35 (20.0)	36/646 (5.6)	4.24 (1.73 to 10.36)
Diabetes mellitus and hypertension	8/57 (14.0)	35/624 (5.6)	2.75 (1.21 to 6.25)

Table 3. Characteristics of RP Patients Who Turned Negative again

Characteristic	RP Patients Turning Negative
Chest CT imaging after discharge, n/total n (%)	
Improvement	37/41 (90.2)
No change	4/41 (9.7)

Deterioration	0/41 (0)
Serum IgG and IgM after discharge, n/total n (%)	
IgG (+) IgM (-)	22/29 (75.9)
IgG (-) IgM (-)	2/29 (6.9)
IgG (+) IgM (+)	5/29 (17.2)
Mean interval of turning positive after discharge (range), day	12.2±5.7 (3-39)
Mean interval of turning negative again (range), day	12.9±13.2 (1-53)
Residual symptoms after turning negative, n/total n (%)	
Chest congestion	2/54 (3.7)
Cough	2/54 (3.7)
Expectoration	1/54 (1.9)
Fatigue	3/54 (5.5)
Palpitation	1/54 (1.9)
Sore throat	1/54 (1.9)

Plus-minus values are means ±SD.

Table S1. Age and Hospital Stay Data Based on Severity

Characteristic	Mild and Moderate Patients	Severe and Critically Ill Patients
Age		
Mean (range) -- year	52.5±14.2 (19-86)	57.8±14.6 (16-94)
Distribution -- n (%)		
0-24	3 (2.1)	7 (0.9)
25-49	51 (36.4)	196 (24.6)
50-74	82 (58.6)	507 (63.5)
≥75	4 (2.9)	88 (11.0)
Mean length of hospital stay (range), day	14.9±8.3 (1-44)	22.4±11.6 (2-59)

Plus-minus values are means ±SD.

Table S2. Linear Regression Analysis Based on 938 Patients

a) Linear regression model for severity

Variable	Coefficients	95% CI (Low)	95% CI (High)	p Value
Sex (male as reference)	0.042	-0.003	0.088	0.069
Age	0.003	0.002	0.005	<0.001 ***

b) Linear regression model of 11 residual symptoms on sex (male as reference)

Residual symptoms	Coefficients	95% CI (Low)	95% CI (High)	p Value
Chest congestion	-0.084	-0.136	-0.033	0.001 **
Cough	-0.058	-0.102	-0.015	0.009 **
Diarrhea	0.011	-0.013	0.035	0.384
Dry eyes	-0.033	-0.074	0.008	0.114
Expectoration	-0.036	-0.080	0.008	0.109
Fatigue	-0.067	-0.109	-0.026	0.001 **
Fever	-0.001	-0.018	0.015	0.879
Headache	-0.057	-0.086	-0.027	<0.001 ***
Myalgia	-0.051	-0.085	-0.017	0.003 **
Palpitation	-0.087	-0.134	-0.040	<0.001 ***
Sore throat	-0.016	-0.048	0.015	0.309

* p < 0.05 **p < 0.01 ***p < 0.001

Table S3. Characteristic of RP and RN patients

Characteristic	RP Patients (n=58)	RN Patients (n=880)	Difference (95% CI)
Mean age (range), year	57.8±13.4 (19-79)	56.9±14.7 (16-94)	0.9 (-3.0 to 4.8)
Mean length of hospital stay (range), day	19.2±9.5 (4-42)	21.4±11.6 (1-59)	-2.2 (-5.3 to 0.8)
Coexisting diseases, n (%)			
Cancer	2 (3.4)	24 (2.7)	0.7 (-3.7 to 5.1)
Cardiac dysfunction	3 (5.2)	12 (1.4)	3.8 (-2.1 to 9.7)
Chronic bronchitis	1 (1.7)	10 (1.1)	0.6 (-2.9 to 4.1)
Coronary artery disease	9 (15.5)	107 (12.2)	3.3 (-5.4 to 12.1)
Diabetes mellitus	11 (19.0)	127 (14.7)	4.8 (-5.2 to 13.8)
Hypertension	21 (36.2)	246 (28.0)	8.2 (-4.8 to 21.3)
Residual symptoms after discharge, n (%)			
Chest congestion	23 (39.7)	170 (19.3)	20.3 (7.1 to 33.6)
Cough	15 (25.9)	109 (12.4)	13.5 (1.7 to 25.3)
Diarrhea	5 (8.6)	29 (3.3)	5.3 (-2.2 to 12.9)
Dry eyes	13 (22.4)	96 (10.9)	11.5 (0.3 to 22.7)
Expectoration	11 (19.0)	117 (13.3)	5.7 (-5.0 to 16.3)
Fatigue	11 (19.0)	100 (11.4)	7.6 (-3.0 to 18.2)
Fever	5 (8.6)	11 (1.3)	7.4 (-0.1 to 14.8)
Headache	5 (8.6)	48 (5.5)	3.2 (-4.4 to 10.8)
Myalgia	6 (10.3)	66 (7.5)	4.1 (-5.4 to 11.1)
Palpitation	13 (22.4)	141 (16.0)	6.4 (-4.9 to 17.8)
Sore throat	6 (10.3)	55 (6.3)	4.1 (-4.1 to 12.3)

For mean age, the difference is given in years; for mean length of hospital stay, the difference is given in days; for other characteristics, the difference is given in percentage points.

Table S4. Age- and Sex-Adjusted Linear Regression Analysis for 11 Residual

a) Chest congestion

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.021 (0.011 to 0.032)	0.005	< 0.001
Age^2	0.000 (0.000 to 0.000)	0.000	< 0.001
Male	-0.024 (-0.076 to 0.027)	0.026	0.350
Re-positive test	0.197 (0.090 to 0.303)	0.054	< 0.001 ***

b) Cough

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.002 (-0.007 to 0.011)	0.005	0.712
Age^2	0.000 (0.000 to 0.000)	0.000	0.762
Male	-0.017 (-0.060 to 0.027)	0.022	0.454
Re-positive test	0.135 (0.045 to 0.224)	0.046	0.003 **

c) Diarrhea

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.003 (-0.002 to 0.008)	0.003	0.242
Age^2	0.000 (0.000 to 0.000)	0.000	0.133
Male	-0.004 (-0.028 to 0.020)	0.012	0.760
Re-positive test	0.053 (0.003 to 0.102)	0.025	0.037 *

d) Dry eyes

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.013 (0.005 to 0.021)	0.004	0.003
Age^2	0.000 (0.000 to 0.000)	0.000	0.001
Male	0.000 (-0.041 to 0.041)	0.021	0.984
Re-positive test	0.250 (0.135 to 0.364)	0.058	0.010 *

e) Expectoration

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.008 (-0.002 to 0.017)	0.005	0.103
Age^2	0.000 (0.000 to 0.000)	0.000	0.059
Male	-0.005 (-0.049 to 0.039)	0.023	0.833
Re-positive test	0.055 (-0.036 to 0.146)	0.047	0.237

f) Fatigue

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.009 (0.000 to 0.017)	0.004	0.041
Age^2	0.000 (0.000 to 0.000)	0.000	0.098
Male	-0.035 (-0.077 to 0.006)	0.021	0.096
Re-positive test	0.073 (-0.012 to 0.159)	0.044	0.094

g) Fever

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.001 (-0.003 to 0.004)	0.002	0.754
Age^2	0.000 (0.000 to 0.000)	0.000	0.690
Male	0.002 (-0.014 to -0.019)	0.008	0.785
Re-positive test	0.074 (0.039 to 0.108)	0.017	< 0.001 ***

h) Headache

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.005 (-0.001 to 0.011)	0.003	0.096
Age^2	0.000 (0.000 to 0.000)	0.000	0.104
Male	-0.007 (-0.036 to 0.023)	0.015	0.659
Re-positive test	0.030 (-0.031 to 0.092)	0.031	0.337

i) Myalgia

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.008 (0.001 to 0.015)	0.004	0.022
Age^2	0.000 (0.000 to 0.000)	0.000	0.020
Male	-0.019 (-0.053 to 0.015)	0.017	0.274
Re-positive test	0.026 (-0.044 to 0.097)	0.036	0.464

j) Palpitation

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.012 (0.002 to 0.021)	0.005	0.019
Age^2	0.000 (0.000 to 0.000)	0.000	0.018
Male	0.004 (-0.044 to 0.051)	0.024	0.879
Re-positive test	0.060 (-0.038 to 0.159)	0.050	0.232

k) Sore throat

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.003 (-0.003 to 0.010)	0.003	0.300
Age^2	0.000 (0.000 to 0.000)	0.000	0.172
Male	-0.014 (-0.046 to 0.018)	0.016	0.391
Re-positive test	0.041 (-0.025 to 0.106)	0.033	0.222

* p < 0.05 **p < 0.01 ***p < 0.001

Table S5. Coexisting Diseases of RP and RN patients above 50

Coexisting diseases, n (%)	RP Patients (n=43)	RN Patients (n=638)	Difference (95% CI)
Diabetes mellitus	10 (23.2)	103 (16.1)	7.1 (-6.3 to 20.6)
Coronary artery disease	9 (20.9)	55 (8.6)	12.3 (-0.5 to 25.1)
Hypertension	20 (46.5)	190 (29.8)	16.7 (0.8 to 32.6)
Diabetes mellitus and coronary artery disease	6 (14.0)	12 (1.9)	12.1 (1.2 to 22.9)
Coronary artery disease and hypertension	7 (16.3)	28 (4.4)	11.9 (0.3 to 23.5)
Diabetes mellitus and hypertension	8 (18.6)	49 (7.7)	10.9 (-1.4 to 23.2)

The difference is given in percentage points.

Table S6. Age- and Sex-Adjusted Linear Regression Analysis for RP Patients over 50

a) Diabetes mellitus

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.019 (-0.007 to 0.045)	0.013	0.151
Age^2	0.000 (0.000 to 0.000)	0.000	0.137
Male	0.005 (-0.044 to 0.054)	0.025	0.843
Diabetes mellitus	0.032 (-0.017 to 0.081)	0.025	0.202

b) Coronary artery disease

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.020 (-0.006 to 0.045)	0.013	0.134
Age^2	0.000 (0.000 to 0.000)	0.000	0.117
Male	0.006 (-0.042 to 0.054)	0.025	0.811
Coronary artery disease	0.089 (0.026 to 0.151)	0.032	0.006 **

c) Hypertension

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.018 (-0.007 to 0.044)	0.013	0.161
Age^2	0.000 (0.000 to 0.000)	0.000	0.141
Male	0.003 (-0.046 to 0.051)	0.025	0.906
Hypertension	0.048 (0.008 to 0.088)	0.020	0.018 *

d) Diabetes mellitus and coronary artery disease

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.021 (-0.004 to 0.046)	0.013	0.102
Age^2	0.000 (0.000 to 0.000)	0.000	0.086
Male	0.007 (-0.041 to 0.055)	0.024	0.778
Diabetes mellitus and coronary artery disease	0.286 (0.173 to 0.398)	0.057	< 0.001 ***

e) Coronary artery disease and hypertension

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.019 (-0.006 to 0.045)	0.013	0.136
Age^2	0.000 (0.000 to 0.000)	0.000	0.122
Male	0.005 (-0.043 to 0.054)	0.025	0.829
Coronary artery disease and diabetes mellitus	0.146 (0.064 to 0.229)	0.042	0.001 **

f) Diabetes mellitus and hypertension

Variable	Coefficients (95% CI)	Coefficients Std. Error	p Value
Age	0.019 (-0.007 to 0.044)	0.013	0.152
Age^2	0.000 (0.000 to 0.000)	0.000	0.133
Male	0.004 (-0.044 to 0.053)	0.025	0.861
Diabetes mellitus and hypertension	0.087 (0.021 to 0.153)	0.034	0.010 *

* p < 0.05 ** p < 0.01 *** p < 0.001

1208 Covid-19 patients were discharged from
Wuhan Union Hospital (West Branch)

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.23.20138149>; this version posted June 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

270 were lost mainly due to wrong phone numbers,
unanswered calls and incoordinate patients

938 finished the first follow-up study

880 had positive nucleic acid test results
after discharge

58 had positive nucleic acid test results
after discharge

2 were lost

56 finished the second follow-up study

2 remained positive

54 turned negative again